SCHEMBL2870547

SCHEMBL2870547

COc1cc2[nH]nc(-c3cc4ccccc4s3)c2cc1C(=O)NC1CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MAPK10 P53779 1/20 0.48
PIP5K1C O60331 1/20 0.46
SIRT2 Q8IXJ6 1/20 0.44
SIRT1 Q96EB6 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.41
KDR P35968 3/20 0.41
CHEK1 O14757 3/20 0.41
AURKA O14965 2/20 0.41
MET P08581 2/20 0.41
TEK Q02763 2/20 0.41
AURKB Q96GD4 2/20 0.41
MAPKAPK2 P49137 1/20 0.41
ALDH1A1 P00352 1/20 0.40
ABL1 P00519 1/20 0.40
LCK P06239 1/20 0.40
LYN P07948 1/20 0.40
FGR P09769 1/20 0.40
PTK2 Q05397 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2864411 0.87 MAPK10 (0.46) MAPK10SIRT2SIRT1KDRAURKA
SCHEMBL13198310 0.87 MAPK10 (0.47) RAB9AL3MBTL1MAPK10PIP5K1CSIRT2
SCHEMBL4337567 0.87 MAPK10 (0.47) RAB9AL3MBTL1MAPK10PIP5K1CSIRT2
SCHEMBL2862938 0.86 MAPK10 (0.50) RAB9AL3MBTL1MAPK10PIP5K1CSIRT2
SCHEMBL2862326 0.85 KDM4E (0.46) MAPK10SIRT2SIRT1KDRCHEK1
SCHEMBL2864604 0.83 RAB9A (0.54) RAB9AL3MBTL1SMN1; SMN2KDRCHEK1
SCHEMBL4338881 0.82 KDM4E (0.53) RAB9AMAPK10SMN1; SMN2ALDH1A1
SCHEMBL2861021 0.82 PIP5K1C (0.46) RAB9AL3MBTL1MAPK10PIP5K1CSIRT2
SCHEMBL4336833 0.81 MAPK10 (0.40) RAB9AMAPK10SIRT2SIRT1MAPKAPK2
SCHEMBL4329239 0.81 MAPK1 (0.45) MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 RAB9A 2355/4885L3MBTL1 2399/4885MAPK10 29/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 RAB9A 2697/4885L3MBTL1 3204/4885MAPK10 27/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 RAB9A 2355/4885L3MBTL1 2399/4885MAPK10 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.